On-going retinal neuronal degeneration despite clinical stability in glaucoma
- 1Center for Devices and Radiological Health (CDRH), US Food and Drug Administration, Silver Spring, MD, USA.
- 2Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Abstract
Glaucoma, a leading cause of irreversible blindness, involves progressive retinal ganglion cell loss. Early detection of this neurodegeneration is critical, yet current clinical methods often identify disease only after substantial damage has occurred. This preliminary study used high-resolution adaptive optics–optical coherence tomography (AO-OCT) to track individual retinal ganglion cells in patients and healthy volunteers over 3 to 5 years. Results revealed higher neurodegeneration in glaucoma compared to normal aging. We observed 4.16 to 6.86% annual decrease in cell density in glaucoma, far exceeding the 0.27% cell loss rate observed in the healthy volunteer group. Critically, AO-OCT detected progression significantly earlier, identifying cell loss 0.74 years before conventional OCT and 1.49 years before visual field testing. These findings demonstrate AO-OCT as a more sensitive tool capable of monitoring glaucomatous damage with superior precision, potentially representing a major advancement over current clinical imaging.
Related
- A synthetic PGC1α co-activator reprograms microglial immunometabolism to preserve cone function in retinal degeneration
- Single-cell spatial transcriptomics of inherited retinal degeneration reveals broad and focal organization of disease responses
- Identification of Kinome Biomarkers and Therapeutic Rescue in cGMP-Linked Retinal Degeneration
- Ocular fluid biomarkers and anti-retinal autoantibodies in neovascular age-related macular degeneration: compartment-specific evidence and a provisional multidomain framework
- Abca4 Knockdown in the Cone-Rich Rodent Psammomys Obesus Leads to Stargardt's Disease-Like Progressive Retinal Degeneration
BibTeX
@article{raghavendra2026ongoing,
title = {{On-going retinal neuronal degeneration despite clinical stability in glaucoma}},
author = {Achyut J. Raghavendra and Kenaan Elbash and Marlon Diaz and Osamah J. Saeedi and Zhuolin Liu and Daniel X. Hammer},
journal = {Science Advances},
year = {2026},
month = nov,
doi = {10.1126/sciadv.aef3222},
url = {https://www.science.org/doi/abs/10.1126/sciadv.aef3222},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - On-going retinal neuronal degeneration despite clinical stability in glaucoma
AU - Achyut J. Raghavendra
AU - Kenaan Elbash
AU - Marlon Diaz
AU - Osamah J. Saeedi
AU - Zhuolin Liu
AU - Daniel X. Hammer
PY - 2026
DA - 2026/11/04
JO - Science Advances
DO - 10.1126/sciadv.aef3222
UR - https://www.science.org/doi/abs/10.1126/sciadv.aef3222
AB - Glaucoma, a leading cause of irreversible blindness, involves progressive retinal ganglion cell loss. Early detection of this neurodegeneration is critical, yet current clinical methods often identify disease only after substantial damage has occurred. This preliminary study used high-resolution adaptive optics–optical coherence tomography (AO-OCT) to track individual retinal ganglion cells in patients and healthy volunteers over 3 to 5 years. Results revealed higher neurodegeneration in glaucoma compared to normal aging. We observed 4.16 to 6.86% annual decrease in cell density in glaucoma, far exceeding the 0.27% cell loss rate observed in the healthy volunteer group. Critically, AO-OCT detected progression significantly earlier, identifying cell loss 0.74 years before conventional OCT and 1.49 years before visual field testing. These findings demonstrate AO-OCT as a more sensitive tool capable of monitoring glaucomatous damage with superior precision, potentially representing a major advancement over current clinical imaging.
SN - 2375-2548
ER -